drugset / Trial / NCT04012827
Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma
NaSingle-groupOpen-labelTreatment
Summary
Apatinib mesylate is a multitarget receptor tyrosine kinase inhibitor. This trial is to evaluate the efficacy and safety of apatinib mesylate combined with doxorubicin and ifosfamide in the treatment of advanced soft tissue sarcoma.
Timeline
- Start
- 2019-08-20
- Primary completion
- 2023-06-15
- Completion
- 2023-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | 50 mg/m2 | — |
| Subject | Ifosfamide | Small molecule | 2.5 g | — |
| Subject | Rivoceranib | Small molecule | 375 mg | — |